dulaglutide vs Liraglutide (Victoza)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
Reported efficacy
Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)
Result source: NCT03495102
Liraglutide (Victoza)
Marketed by Novo Nordisk
NCT00318461 · Phase 3 · completed
This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.
Next expected readout: June 2027 · NCT03883412 (registry estimate)
Reported efficacy
Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00318461
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dulaglutide | Liraglutide (Victoza) |
|---|---|---|
| HbA1c, change | -2.0% vs -1.1%−0.9 vs placeboNCT0459162625 other results
| -0.6% vs 0.4%−1.1 vs placeboNCT0154121527 other results
|
| Body weight, change (kg) | -0.8 vs 0.4−1.2 vs placeboNCT0459162618 other results
| -2.3 vs 1.0−3.3 vs placeboNCT0154121522 other results
|
| HbA1c below 7% | 75.9% vs 33.8%+42.1 vs placeboNCT045916268 other results
| 63.7% vs 36.5%+27.2 vs placeboNCT015412153 other results
|
| Fasting plasma glucose, change | -2.2 vs -2.4vs Insulin GlargineNCT016485823 other results
| -1.6 vs 1.0−2.6 vs placeboNCT0154121521 other results
|
| 3-point MACE (% with event) | 12% vs 13.4%−1.4 vs placeboNCT013949521 other result
| 13% vs 14.9%−1.9 vs placeboNCT01179048 |
HbA1c, change
- dulaglutide
- -2.0% vs -1.1%−0.9 vs placeboNCT04591626
25 other results
- -1.3% vs -0.5% NCT02597049
- -1.3% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.4% vs -0.7% NCT02152371
- -1.4% vs -0.1% NCT01769378
- -1.2% vs -1.1% NCT01621178
- -1.7% vs -1.2% NCT01648582
- -1.5% vs -0.9% NCT01644500
- -1.4% vs -1.4% NCT01624259
- -1.1% vs -1.1% NCT01621178
- -1.3% vs -1.2% NCT01648582
- -1.2% vs -0.9% NCT01644500
- -1.4% vs -0.9% NCT01584232
- -1% vs 0.5% NCT02963766
- -0.5% vs 0.5% NCT02963766
- -0.9% vs -1.7% NCT04255433
- -1.1% vs -1% NCT01621178
- -1.5% vs -0.9% NCT01648582
- -1.1% vs -1% NCT01621178
- -1.0% vs -0.9% NCT01648582
- -1.4% vs -0.4% NCT02973100
- -1.3% vs -0.4% NCT02973100
- -1.2% vs -0.4% NCT02973100
- -1.4% vs 0.1% NCT02750410
- Liraglutide (Victoza)
- -0.6% vs 0.4%−1.1 vs placeboNCT01541215
27 other results
- -1% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -1.0% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -0.7% vs -1.0% NCT00318461
- -0.4% vs -0.5% NCT00318461
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -0.7% vs 0.7% NCT01541215
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- 7.9% vs 8.9% NCT01505673
- 6.4% vs 6.4% NCT02765399
- -1.1% vs -0.5% NCT01907854
- -1.8% vs -1.2% NCT01973231
- -1.7% vs -1.0% NCT02008682
- 4.1% vs 3.4% NCT01966978
- -1.4% vs -1.1% NCT02730377
- -1.3% vs -0.7% NCT01917656
- -1.1% vs 0.2% NCT00318422
Body weight, change (kg)
- dulaglutide
- -0.8 vs 0.4−1.2 vs placeboNCT04591626
18 other results
- -1.9 vs 0.5 NCT02152371
- -0.9 vs -0.2 NCT01769378
- -2.7 vs 1.6 NCT01621178
- -1.1 vs 1.4 NCT01648582
- -2.8 vs 1.1 NCT01621178
- -1.5 vs 1.0 NCT01648582
- -1.5 vs 0.9 NCT01644500
- -2.9 vs -3.6 NCT01624259
- -1.7 vs 1.6 NCT01621178
- -0.8 vs 1.4 NCT01648582
- -2.0 vs 1.1 NCT01621178
- -0.9 vs 1.0 NCT01648582
- -0.8 vs 0.9 NCT01644500
- -0.5 vs 0.9 NCT01584232
- -4.1 vs -1.6 NCT02973100
- -3.9 vs -1.6 NCT02973100
- -2.8 vs -1.6 NCT02973100
- -0.2 vs -0.3 NCT02750410
- Liraglutide (Victoza)
- -2.3 vs 1.0−3.3 vs placeboNCT01541215
22 other results
- -2.5 vs -0.9 NCT01541215
- -2.8 vs 0.9 NCT00318461
- -2.9 vs 0.7 NCT00318461
- -2.6 vs 0.9 NCT00318461
- -3.0 vs 0.7 NCT00318461
- -1.8 vs 0.9 NCT00318461
- -2.1 vs 0.7 NCT00318461
- 2.9 vs 4.1 NCT02607306
- -1 vs 4.1 NCT02607306
- 0.2 vs 1.3 NCT03172494
- -2.5 vs 1.3 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 0.5 vs 2.2 NCT02501161
- -1.4 vs 1.8 NCT01952145
- 1.2 vs 3 NCT02501161
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- -3.8 vs -3.5 NCT02730377
- -3.3 vs -1.8 NCT01907854
- -4.2 vs -3.7 NCT01973231
- -5.4 vs -1.5 NCT01917656
- -0.6 vs 3.1 NCT01966978
HbA1c below 7%
- dulaglutide
- 75.9% vs 33.8%+42.1 vs placeboNCT04591626
8 other results
- 37.5% vs 34.6% NCT01621178
- 32.9% vs 29.1% NCT01621178
- 31.7% vs 34.6% NCT01621178
- 33.5% vs 29.1% NCT01621178
- 68.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 0% vs 47.4% NCT02750410
- Liraglutide (Victoza)
- 63.7% vs 36.5%+27.2 vs placeboNCT01541215
3 other results
- 51.8% vs 23.2% NCT02964247
- 76.5% vs 52.6% NCT02008682
- 44% vs 20% NCT01966978
Fasting plasma glucose, change
- dulaglutide
- -2.2 vs -2.4vs Insulin GlargineNCT01648582
3 other results
- -2.4 vs -2.6 NCT01648582
- -1.5 vs -2.4 NCT01648582
- -1.7 vs -2.6 NCT01648582
- Liraglutide (Victoza)
- -1.6 vs 1.0−2.6 vs placeboNCT01541215
21 other results
- -1.1 vs 0.8 NCT01541215
- -1.7 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.6 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.1 vs -1.3 NCT00318461
- -0.8 vs -0.6 NCT00318461
- -4.1 vs -4.0 NCT02607306
- -2.6 vs -4.0 NCT02607306
- -3.6 vs -3.5 NCT03172494
- -3.9 vs -3.7 NCT02501161
- -1.9 vs -3.5 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -4.0 vs -3.8 NCT02501161
- -2.8 vs -2.3 NCT02911948
- 6.4 vs 6.4 NCT02765399
- -2.2 vs -1.2 NCT02730377
- -2.9 vs -1.6 NCT01973231
- -2.3 vs -1.2 NCT02008682
- -0.1 vs 0.1 NCT01917656
- -1.8 vs -0.6 NCT01917656
3-point MACE (% with event)
- dulaglutide
- 12% vs 13.4%−1.4 vs placeboNCT01394952
1 other result
- 13.1% vs 12.2% NCT04255433
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. dulaglutide: 11 of 11 rows · Liraglutide (Victoza): 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dulaglutide Rows use multiple source trials | Liraglutide (Victoza) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -0.1 vs 0 placebo kg @ 26wk1.5 mga,b,c NCT02963766 · Phase 3 show 1 more dose-0.2 vs 0 placebo kg @ 26wk0.75 mg NCT02963766 · Phase 3 | -1.02 vs -0.72 placebo kg @ 26wkb,c NCT02964247 · Phase 3 · registry result, not featured evidence |
| Fasting Plasma Glucose Change mg/dL absolute change · mg | -34.81 vs -34.25 Liraglutide mg @ 26wk1.5 mg weeklyb,c NCT01624259 · Phase 3 · registry result, not featured evidence | -27 vs -11.97 placebo mg @ 26wkb,c NCT02964247 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -1.5% (n=383) @ 52wk1.5 mga,b,c,d NCT04809220 · Phase 3 · registry result, not featured evidence show 1 more dose-1.19% (n=193) @ 52wk0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence | -2.02% (n=200) @ 32wka,b,c,d NCT02298192 · Phase 3 · registry result, not featured evidence show 1 more dose-2.01% (n=189) @ 32wk NCT02298192 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain responder rate · % of participants | 51.8% (n=139) vs 21.1% (n=147) placebo @ 28wk1.5 mge,b,c,f NCT04591626 · Phase 3 · registry result, not featured evidence · add on | 47.69% (n=195) vs 19.15% (n=94) placebo @ 26wke,b,c,f Yes NCT02964247 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Weight Gain responder rate · % of participants | 51.8% (n=139) vs 21.1% (n=147) placebo @ 28wk1.5 mge,b,c,f NCT04591626 · Phase 3 · registry result, not featured evidence · add on | 47.69% (n=195) vs 19.15% (n=94) placebo @ 26wke,b,c,f Yes NCT02964247 · Phase 3 · registry result, not featured evidence |
| Postprandial Glucose AUC absolute change · mg | -238.46 vs 15.56 placebo mg @ 4wkg,b,c,h NCT03315780 · Phase 4 · registry result, not featured evidence | 5678 vs 5557 placebo mgg,b,c,h NCT01937598 · Phase 3 · registry result, not featured evidence |
| Weight percent change · % of baseline | -4.82% (n=6578) vs -11.6% (n=6586) Tirzepatide @ 156wk1.5 mgb,c,i NCT04255433 · Phase 3 · registry result, not featured evidence | -7.2% (n=35) vs -3.1% (n=37) placebo @ 84wkb,c,i NCT01234649 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 0.3%j NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results4.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.8%4.5 mg NCT03495102 · Phase 3 10.9%3 mg NCT03495102 · Phase 3 9.2%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 3.8%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 3.9%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 2.5%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence 2.2%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.1%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 4.9%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 3.5%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 8% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 12.4%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 14.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 10.4% NCT01769378 · Phase 3 · registry result, not featured evidence 9%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 9.7%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 10%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 9.2%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 5.1%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 16.7% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 21.1%1.8 mg dailyk NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results18.3%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 3% NCT01179048 · Phase 3 15.2%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 41.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 55.2%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 6.3% NCT02765399 · Phase 4 · registry result, not featured evidence 22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 8.6% NCT01505673 · Phase 4 · registry result, not featured evidence 7.9% NCT01907854 · Phase 4 · registry result, not featured evidence 5.4% NCT01973231 · Phase 4 · registry result, not featured evidence 14.7% NCT02008682 · Phase 4 · registry result, not featured evidence 15.1% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 16.1%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 55.1% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4% NCT03175120 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 1.5% NCT02964247 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 3.7%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —j NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results1.7% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%4.5 mg NCT03495102 · Phase 3 1.1%3 mg NCT03495102 · Phase 3 0.8%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 0%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 1.7%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence —1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.4%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 4% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 2.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.3%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.2% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 0.4%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 6%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 2.6%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 1.3%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 8.3% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 12%1.8 mg dailyk NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.5%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.5%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT01179048 · Phase 3 0%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 — NCT03260881 · Phase 4 · registry result, not featured evidence 7.4% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 7.9%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence — NCT02765399 · Phase 4 · registry result, not featured evidence — NCT01966978 · Phase 4 · registry result, not featured evidence · combination — NCT02014740 · Phase 4 · registry result, not featured evidence — NCT02299388 · Phase 4 · registry result, not featured evidence — NCT01505673 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01973231 · Phase 4 · registry result, not featured evidence — NCT02008682 · Phase 4 · registry result, not featured evidence 6.4% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 8.3%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence — NCT01234649 · Phase 3 · registry result, not featured evidence · combination 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence — NCT02964247 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.2%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 40.3%j NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results5% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%4.5 mg NCT03495102 · Phase 3 7.3%3 mg NCT03495102 · Phase 3 8.7%1.5 mg NCT03495102 · Phase 3 21.4%1.5 mg NCT01621178 · Phase 3 25.3%0.75 mg NCT01621178 · Phase 3 —1.5 mg NCT02963766 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 4%1.5 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 0%1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence 0%0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence 2.5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence 0% NCT03315780 · Phase 4 · registry result, not featured evidence 31.9%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence 3.8%1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.6%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence 5.6%1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 3.5%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 2.1%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 6% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 9.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 5.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 3.8% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.6%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.7%1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence —LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 3.9%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 8.9%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence 3.7%1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 9.1%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0% NCT01458210 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 0% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 6.6%1.8 mg dailyk NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results10.4%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 49.7% NCT01179048 · Phase 3 13.6%1.8 mg NCT01541215 · Phase 3 13.5%1.8 mg NCT01541215 · Phase 3 4.2%1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 38.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 9.4%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 0% NCT02765399 · Phase 4 · registry result, not featured evidence 11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 2.9% NCT01505673 · Phase 4 · registry result, not featured evidence 3% NCT01907854 · Phase 4 · registry result, not featured evidence 5.9% NCT01973231 · Phase 4 · registry result, not featured evidence 1.6% NCT02008682 · Phase 4 · registry result, not featured evidence 1.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 0% NCT02889510 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 7.8%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 2.5% NCT02964247 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 5.1%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 0% NCT01937598 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | j nausea 14.9% (placebo 5.4%) diarrhoea 13.5% (placebo 8.8%) nasopharyngitis 11.4% (placebo 10.8%) NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 41 more resultsnasopharyngitis 27.1% diarrhoea 12.2% nausea 9.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5 mg diarrhoea 21.2% (placebo 13.7%) headache 15.4% (placebo 9.8%) nausea 15.4% (placebo 7.8%) NCT02963766 · Phase 3 1.5 mg diarrhoea 12% (placebo 13.7%) nausea 12% (placebo 7.8%) abdominal pain upper 10% (placebo 7.8%) NCT02963766 · Phase 3 0.75 mg vomiting 17.6% (placebo 3.9%) diarrhoea 15.7% (placebo 13.7%) headache 13.7% (placebo 9.8%) NCT02963766 · Phase 3 0.75 mg headache 10.2% (placebo 9.8%) vomiting 8.2% (placebo 3.9%) abdominal pain 6.1% (placebo 5.9%) NCT02963766 · Phase 3 1.5 mg gastritis 14.3% dyslipidaemia 9.5% nausea 9.5% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg anaemia 21.4% gastritis 14.3% dyslipidaemia 7.1% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 15.8% (placebo 30.8%) abdominal discomfort 8.3% (placebo 12.8%) constipation 6.7% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 28.3% (placebo 30.8%) constipation 10.8% (placebo 12.8%) abdominal discomfort 9.2% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence influenza 16.7% (placebo 0%) decreased appetite 8.3% (placebo 0%) diarrhoea 8.3% (placebo 8.3%) NCT03315780 · Phase 4 · registry result, not featured evidence 1.5 mg nausea 22.3% diarrhoea 18.9% covid-19 15.1% NCT04255433 · Phase 3 · registry result, not featured evidence 1.5 mg constipation 12.5% diarrhoea 10.2% pyrexia 10% NCT04809220 · Phase 3 · registry result, not featured evidence 0.75 mg constipation 8.7% nasopharyngitis 8.7% covid-19 8.2% NCT04809220 · Phase 3 · registry result, not featured evidence 1.5 mg decreased appetite 22.2% (placebo 4.1%) diabetic nephropathy 13.9% (placebo 15%) diarrhoea 13.2% (placebo 8.2%) NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.5 mg nausea 14.8% (placebo 3.6%) back pain 9.2% (placebo 7.1%) viral upper respiratory tract infection 6.3% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence 0.75 mg diarrhoea 9.9% (placebo 2.9%) back pain 8.5% (placebo 7.1%) viral upper respiratory tract infection 5.7% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence nausea 12% (placebo 1.3%) diarrhoea 11.3% (placebo 4%) upper respiratory tract infection 7.3% (placebo 6.7%) NCT02152371 · Phase 3 · registry result, not featured evidence · combination 1.5 mg hyperlipidaemia 17.8% diarrhoea 16.7% lipase increased 10.5% NCT01648582 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 19.5% diarrhoea 10.9% hypertension 10.9% NCT01648582 · Phase 3 · registry result, not featured evidence nausea 10.5% (placebo 0%) diarrhoea 8.4% (placebo 0%) eructation 5.9% (placebo 0%) NCT01769378 · Phase 3 · registry result, not featured evidence 1.5 mg diarrhoea 17.2% hyperlipidaemia 11.1% nausea 10.2% NCT01644500 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 12.1% diarrhoea 7.3% lipase increased 5.6% NCT01644500 · Phase 3 · registry result, not featured evidence 1.5 mg weekly nausea 20.4% diarrhoea 12% dyspepsia 8% NCT01624259 · Phase 3 · registry result, not featured evidence 4.5 mg nausea 30.3% (placebo 4.9%) diarrhoea 21.1% (placebo 11.1%) vomiting 13.2% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 3.0 mg nausea 25.3% (placebo 4.9%) diarrhoea 22.8% (placebo 11.1%) decreased appetite 16.5% (placebo 1.2%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg nausea 22.2% (placebo 4.9%) diarrhoea 11.1% (placebo 11.1%) vomiting 11.1% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) blood pressure decreased 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 1.5 mg abdominal discomfort 10% (placebo 6.3%) decreased appetite 10% (placebo 0%) nausea 10% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg abdominal discomfort 9.1% (placebo 6.3%) nausea 9.1% (placebo 0%) vomiting 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal distension 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg abdominal discomfort 0% (placebo 6.3%) abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal pain 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence headache 41.2% nausea 41.2% vomiting 35.3% NCT01458210 · Phase 1 · registry result, not featured evidence · combination diarrhoea 8% haemorrhoids 4% injection site pain 4% NCT01432938 · Phase 1 · registry result, not featured evidence · combination vomiting 11.5% decreased appetite 7.7% headache 7.7% NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy gastrooesophageal reflux disease 33.3% atrioventricular block first degree 28.6% headache 28.6% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 1.8 mg dailyk nausea 21.5% diarrhoea 16.5% nasopharyngitis 14.9% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 32 more results1.2 mg daily nausea 17.5% nasopharyngitis 15% headache 14.2% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6 mg daily nasopharyngitis 17.8% diarrhoea 12.8% nausea 12.4% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.8 mg nausea 28.8% (placebo 13.2%) vomiting 25.8% (placebo 8.8%) diarrhoea 22.7% (placebo 16.2%) NCT01541215 · Phase 3 1.8 mg nasopharyngitis 3.8% (placebo 27.9%) vomiting 3.8% (placebo 8.8%) abdominal pain 1.9% (placebo 7.4%) NCT01541215 · Phase 3 1.8 mg hyperglycaemia 2.1% (placebo 5.9%) pharyngitis 2.1% (placebo 5.9%) abdominal pain 0% (placebo 7.4%) NCT01541215 · Phase 3 abdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 14.3%) NCT02765399 · Phase 4 · registry result, not featured evidence gi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nausea 29.1% NCT02014740 · Phase 4 · registry result, not featured evidence nausea 31.4% (placebo 19.4%) decreased in apetite 17.1% (placebo 11.1%) diarrhea 11.4% (placebo 8.3%) NCT01505673 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 16.3% decreased appetite 8.9% NCT01907854 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 12.4% lipase increased 8.4% NCT01973231 · Phase 4 · registry result, not featured evidence nausea 14.8% decreased appetite 10.9% diarrhoea 8.2% NCT02008682 · Phase 4 · registry result, not featured evidence vomiting 5.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination gastrointestinal disorders 27.1% (placebo 5.7%) general disorders and administration site conditions 2.9% (placebo 0%) nervous system disorders 2.9% (placebo 2.9%) NCT02889510 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence decreased appetite 14.4% diarrhoea 14.4% lipase increased 12.2% NCT03172494 · Phase 3 · registry result, not featured evidence nausea 37.2% (placebo 2.7%) diarrhea 17.9% (placebo 17.3%) allergic reaction to liraglutide 1.3% (placebo 0%) NCT01234649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nausea 26.2% (placebo 6%) decreased appetite 9.4% (placebo 0%) diarrhoea 9.4% (placebo 3%) NCT02964247 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 34.4% constipation 13.9% diarrhoea 8.8% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence headache 12.5% (placebo 12.5%) asympomatic hyppglycaemia 6.3% (placebo 0%) nausea 6.3% (placebo 0%) NCT01937598 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 32 weeks versus 52 weeks.
- eThe reported result categories differ.
- fAssessment timepoints differ: 26 weeks versus 28 weeks.
- gTrial phases differ: Phase 3 versus Phase 4.
- hThe assessment timepoint is not available for both results.
- iAssessment timepoints differ: 84 weeks versus 156 weeks.
- jPopulation comparability has not been reviewed for 44 of these studies.
- kPopulation comparability has not been reviewed for 32 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dulaglutide
show 4 more results
show 2 more results
show 4 more results
show 3 more results
show 1 more result
show 2 more results
+ 53 further endpoints in the CSV export.
Liraglutide (Victoza)
show 1 more result
show 8 more results
show 7 more results
show 3 more results
show 1 more result
show 2 more results
show 8 more results
show 8 more results
+ 117 further endpoints in the CSV export.
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: December 2030 · NCT07282041 (registry estimate)
Reported efficacy
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 (met)
Result source: NCT01394952
Liraglutide (Victoza)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dulaglutide | Liraglutide (Victoza) |
|---|---|---|
| LDL-C, % change | —Trial running · NCT07282041 | —Not reported |
| Non-HDL-C, % change | —Trial running · NCT07282041 | —Not reported |
| ApoB, % change | —Trial running · NCT07282041 | —Not reported |
| Lp(a), % change | —Trial running · NCT07282041 | —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT07282041 | 13% vs 14.9%−1.9 vs placeboNCT01179048 |
LDL-C, % change
- dulaglutide
- —Trial running · NCT07282041
- Liraglutide (Victoza)
- —Not reported
Non-HDL-C, % change
- dulaglutide
- —Trial running · NCT07282041
- Liraglutide (Victoza)
- —Not reported
ApoB, % change
- dulaglutide
- —Trial running · NCT07282041
- Liraglutide (Victoza)
- —Not reported
Lp(a), % change
- dulaglutide
- —Trial running · NCT07282041
- Liraglutide (Victoza)
- —Not reported
3-point MACE (% with event)
- dulaglutide
- —Trial running · NCT07282041
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. dulaglutide: 0 of 4 rows · Liraglutide (Victoza): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Victoza) |
|---|---|
| Dropout rate | 3%a NCT01179048 · Phase 3 show 3 more results0% NCT03260881 · Phase 4 · registry result, not featured evidence 10% NCT04881110 · Phase 4 · registry result, not featured evidence 0% NCT03010683 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01179048 · Phase 3 show 3 more results— NCT03260881 · Phase 4 · registry result, not featured evidence — NCT04881110 · Phase 4 · registry result, not featured evidence — NCT03010683 · Phase na · registry result, not featured evidence |
| Serious AEs | 49.7%a NCT01179048 · Phase 3 show 3 more results0% NCT03260881 · Phase 4 · registry result, not featured evidence 0% NCT04881110 · Phase 4 · registry result, not featured evidence 0% NCT03010683 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultabdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Victoza)
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Liraglutide (Victoza)'s landscape